1. Home
  2. SN vs INCY Comparison

SN vs INCY Comparison

Compare SN & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharkNinja Inc.

SN

SharkNinja Inc.

N/A

Current Price

$166.16

Market Cap

21.1B

Sector

N/A

ML Signal

N/A

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$127.62

Market Cap

17.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SN
INCY
Founded
1993
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1B
17.0B
IPO Year
2023
1994

Fundamental Metrics

Financial Performance
Metric
SN
INCY
Price
$166.16
$127.62
Analyst Decision
Strong Buy
Buy
Analyst Count
8
21
Target Price
$133.13
$103.52
AVG Volume (30 Days)
1.5M
1.1M
Earning Date
05-06-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
4173.33
EPS
1.77
1.47
Revenue
$6,399,188,000.00
$3,394,635,000.00
Revenue This Year
$15.22
$10.44
Revenue Next Year
$10.74
$10.99
P/E Ratio
$96.66
$83.45
Revenue Growth
15.75
13.67
52 Week Low
$83.12
$81.09
52 Week High
$194.54
$132.60

Technical Indicators

Market Signals
Indicator
SN
INCY
Relative Strength Index (RSI) 47.93 54.63
Support Level $142.57 $121.61
Resistance Level $192.88 $131.13
Average True Range (ATR) 7.12 3.07
MACD -2.20 -0.51
Stochastic Oscillator 37.52 59.02

Price Performance

Historical Comparison
SN
INCY

About SN SharkNinja Inc.

SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment, and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The Company has identified two operating segments, Domestic and International. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: